Skip to main content
. 2017 Apr 26;8(28):45898–45917. doi: 10.18632/oncotarget.17438

Figure 5. Upregulation of anti-apoptotic BCL2 proteins by activated MAPK and PI3K/AKT pathway.

Figure 5

(A) Expression of BCL-XL, BCL-2 and MCL-1 in A431-ΔRAF-1/ERTam cells with or without 4-OHT pre-incubation. To prevent new protein synthesis cells were treated with cycloheximide (CHX, 10 mg/mL) for indicated periods. (B, C) Expression of BCL-XL, BCL-2 and MCL-1 in A431-myr-AKT/ERTam (B) and Difi-myr-AKT/ERTam (C) cells treated with cetuximab (1 μg/ml) for indicated periods. (D) Relative BAK transcript level in A431-myr-AKT/ERTam cells treated with cetuximab (1 μg/ml) for indicated periods with or without 4-OHT. Expression levels of BAK were normalized to the housekeeping gene beta-ACTIN. Mean change (+ SD) of BAK transcript levels from three independent experiments are given.